I think that looks pretty fair.... as a base valuation.
provided we were looking at double digit growth like BioReliance was; and all the other usual ratios similar as well.
Other variables could push the ratios higher; like for example if KBLB was in an exclusive JV agreement with a Fortune 100 company, or if other products that WERE NOT apparent in KBLB business plan came into fruition, dominance in the industry, mangement, scientists, universities will all be a backdrop to a higher valuation IN TIME.
IMO, the IR/PR of KBLB is just in starting mode now, that puts one of my concerns to rest.
Are the markets in the U.S. open tomorrow?